AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32449254 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir
Number of subjects: 5
Study 34511016 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 208
Study 34511016 — intervention group
Group type: COMPARATOR
Intervention: sleep education
Number of subjects: 208
Study 33357246 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative physical activity
Number of subjects: 640
Study 33357246 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative physical activity
Number of subjects: 640
Study 33357246 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 640
Study 34747807 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRE therapy
Number of subjects: 30
Study 34747807 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 30
Study 32766852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy for CNS+ patients in the international randomized phase 3 trial Inter-B-NHL-ritux 2010
Number of subjects: 217
Study 32766852 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, oncovin (vincristine), prednisone prephase
Number of subjects: 217
Study 33908815 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinising hormone (LH) supplementation (Group A)
Number of subjects: 0
Study 33908815 — intervention group
Group type: COMPARATOR
Intervention: Control group without LH supplementation (Group B)
Number of subjects: 0
Study 33753034 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 3663
Study 33753034 — intervention group
Group type: COMPARATOR
Intervention: Medically managed patients
Number of subjects: 3663
Study 32815648 — intervention group
Group type: EXPERIMENTAL
Intervention: HERB system + standard lifestyle modification
Number of subjects: 0
Study 32815648 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle modification alone
Number of subjects: 0
Study 36302195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 0
Study 36302195 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 0
Study 36302195 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning
Number of subjects: 0
Study 36302195 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen paired with awake prone positioning
Number of subjects: 0
Study 33823974 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT intervention
Number of subjects: 791
Study 33823974 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 791
Study 34387826 — intervention group
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Oxygen (HFNO)
Number of subjects: 50
Study 34387826 — intervention group
Group type: COMPARATOR
Intervention: Conventional Oxygen Therapy
Number of subjects: 50
Study 35367279 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 800 mg
Number of subjects: 78
Study 35367279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 33761149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 679
Study 33761149 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 679
Study 32339504 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 349
Study 32339504 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 349
Study 35197331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored 2-day educational course on skin cancer management
Number of subjects: 54
Study 34979245 — intervention group
Group type: COMPARATOR
Intervention: High-Definition White Light Colonoscopy (HDWLE)
Number of subjects: 1203
Study 34979245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff (CF) (Endocuff Vision)
Number of subjects: 1203
Study 34979245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap (CP) (Reveal)
Number of subjects: 1203
Study 32756922 — intervention group
Group type: EXPERIMENTAL
Intervention: PXS group
Number of subjects: 38
Study 32756922 — intervention group
Group type: COMPARATOR
Intervention: Non-PXS group
Number of subjects: 38
Study 33367925 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching for 60 seconds
Number of subjects: 100
Study 33367925 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching for 30 seconds
Number of subjects: 100
Study 33367925 — intervention group
Group type: COMPARATOR
Intervention: Stretching for 15 seconds
Number of subjects: 100
Study 33367925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretch)
Number of subjects: 100
Study 32485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 32485734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33002752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator interval approach in-plane
Number of subjects: 120
Study 33002752 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotator interval approach out-of-plane
Number of subjects: 120
Study 33002752 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach in-plane
Number of subjects: 120
Study 33002752 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach out-of-plane
Number of subjects: 120
Study 33002752 — intervention group
Group type: COMPARATOR
Intervention: Posterior glenohumeral approach
Number of subjects: 120
Study 32876405 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.2 mg (group C)
Number of subjects: 120
Study 32876405 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (group T)
Number of subjects: 120
Study 32876405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg (group P)
Number of subjects: 120
Study 32876405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group O)
Number of subjects: 120
Study 34210732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 42554
Study 34210732 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy after positive FIT
Number of subjects: 42554
Study 33977835 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Partial ROM (100°‐65°)
Number of subjects: 45
Study 33977835 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Partial ROM (65°‐30°)
Number of subjects: 45
Study 33977835 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ROM (100°‐30°)
Number of subjects: 45
Study 33977835 — intervention group
Group type: EXPERIMENTAL
Intervention: Varied ROM (daily alternation between INITIALROM and FINALROM)
Number of subjects: 45
Study 33977835 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training control)
Number of subjects: 45
Study 34478028 — intervention group
Group type: EXPERIMENTAL
Intervention: IV milrinone (0.5 µg/kg/min, median duration of infusion 5 days)
Number of subjects: 94
Study 34478028 — intervention group
Group type: EXPERIMENTAL
Intervention: IV milrinone
Number of subjects: 94
Study 34478028 — intervention group
Group type: COMPARATOR
Intervention: Control (hypertension alone)
Number of subjects: 94
Study 35716937 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D flow automated dynamic method
Number of subjects: 50
Study 35716937 — intervention group
Group type: COMPARATOR
Intervention: Static planar method
Number of subjects: 50
Study 33236687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubridge flow diverter (FD)
Number of subjects: 200
Study 34996347 — intervention group
Group type: EXPERIMENTAL
Intervention: WBF-011 (5-strain novel probiotic formulation)
Number of subjects: 104
Study 34996347 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 104
Study 35586668 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor chemotherapy combined with Lung Cancer Fang No. 1 treatment
Number of subjects: 80
Study 35586668 — intervention group
Group type: COMPARATOR
Intervention: PD-1/PD-L1 inhibitor chemotherapy
Number of subjects: 80
Study 34255269 — intervention group
Group type: EXPERIMENTAL
Intervention: HD–EAM group
Number of subjects: 100
Study 34255269 — intervention group
Group type: COMPARATOR
Intervention: Merge group
Number of subjects: 100
Study 34255269 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 37013726 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dermoscopy e‐learning course (4 h) with mandatory refreshers
Number of subjects: 233
Study 37013726 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dermoscopy e‐learning course (4 h) with optional refreshers
Number of subjects: 233
Study 37013726 — intervention group
Group type: EXPERIMENTAL
Intervention: Long dermoscopy training course (12 h) with mandatory refreshers
Number of subjects: 233
Study 37013726 — intervention group
Group type: EXPERIMENTAL
Intervention: Long dermoscopy training course (12 h) with optional refreshers
Number of subjects: 233
Study 33606920 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate eGFR variability (>6.4 to ≤12.1)
Number of subjects: 8241
Study 33606920 — intervention group
Group type: EXPERIMENTAL
Intervention: High eGFR variability (>12.1)
Number of subjects: 8241
Study 33606920 — intervention group
Group type: COMPARATOR
Intervention: Low eGFR variability (≤6.4)
Number of subjects: 8241
Study 36315349 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 0
Study 36315349 — intervention group
Group type: COMPARATOR
Intervention: Low Molecular Weight Heparins (LMWHs)
Number of subjects: 0
Study 33691772 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Behavioral Health (IBH) intervention including a 24-month supported practice change process, online curriculum, practice redesign workbook, remote quality improvement coaching, and online learning community.
Number of subjects: 3375
Study 33691772 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 3375
Study 32761445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leukoplakia cases with etiological factors (smoking, alcohol consumption)
Number of subjects: 107
Study 36262763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy (DBT)
Number of subjects: 210
Study 36262763 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 210
Study 34847898 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice containing CPP
Number of subjects: 33
Study 34847898 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice containing PVM/MA
Number of subjects: 33
Study 34847898 — intervention group
Group type: COMPARATOR
Intervention: Regular toothpaste (Control)
Number of subjects: 33
Study 32617646 — intervention group
Group type: EXPERIMENTAL
Intervention: tolcapone (100 mg TID for 5 days)
Number of subjects: 55
Study 35715930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amyloid-PET (ARM1)
Number of subjects: 840
Study 35715930 — intervention group
Group type: EXPERIMENTAL
Intervention: Late amyloid-PET (ARM2)
Number of subjects: 840
Study 35715930 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-choice (ARM3)
Number of subjects: 840
Study 32232608 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral incremental VOR adaptation training (10 sessions over 12 days)
Number of subjects: 10
Study 34609084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE)
Number of subjects: 40
Study 34609084 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment
Number of subjects: 40
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: ARSER
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: empirical‐JTK
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: GeneCycle
Number of subjects: 0
Study 32182235 — intervention group
Group type: COMPARATOR
Intervention: naive method
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomb Scargle
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: RAIN
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: JTK
Number of subjects: 0
Study 32182235 — intervention group
Group type: EXPERIMENTAL
Intervention: meta2d
Number of subjects: 0
Study 34408396 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging Only group
Number of subjects: 66
Study 34408396 — intervention group
Group type: COMPARATOR
Intervention: Full Exam group
Number of subjects: 66
Study 34408396 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 33025146 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical guide made using cone beam computed tomography (CBCT) and dental cast (Group I)
Number of subjects: 0
Study 33025146 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical guide made using only CBCT data (Group II)
Number of subjects: 0
Study 33025146 — intervention group
Group type: COMPARATOR
Intervention: No surgical guide (Group III)
Number of subjects: 0
Study 33250211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sowing of native perennial grass seed (Anthephora pubescens, Chloris gayana, Cynodon dactylon, Digitaria eriantha, Eragrostis curvula, Panicum maximum, Themeda triandra)
Number of subjects: 48
Study 33250211 — intervention group
Group type: COMPARATOR
Intervention: Clearing of Parthenium hysterophorus
Number of subjects: 48
Study 33250211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sowing of native perennial grass seed
Number of subjects: 48
Study 33048154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n=153) with 4 weekly, 4 biweekly, and 3 monthly counseling sessions and choice of cessation medication.
Number of subjects: 303
Study 33048154 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=150) with 4 weekly counseling sessions and medication advice.
Number of subjects: 303
Study 33048154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (n=153) participants reporting cessation medication use.
Number of subjects: 303
Study 33048154 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (n=150) participants reporting cessation medication use.
Number of subjects: 303
Study 33048154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group adverse events (n=153).
Number of subjects: 303
Study 33048154 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group adverse events (n=150).
Number of subjects: 303
Study 35718070 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Endoscopy AI‐assisted Diagnosis System (GEADS)
Number of subjects: 105573
Study 35718070 — intervention group
Group type: COMPARATOR
Intervention: Endoscopists (novice and expert)
Number of subjects: 105573
Study 32981714 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in occlusal vertical dimension (OVD) by 3, 6, and 9 mm
Number of subjects: 25
Study 32981714 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in occlusal vertical dimension (OVD) by 3 mm
Number of subjects: 25
Study 32981714 — intervention group
Group type: COMPARATOR
Intervention: Original OVD
Number of subjects: 25
Study 33002440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 0
Study 33002440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32441857 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg thrice daily)
Number of subjects: 16
Study 32441857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32441857 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 16
Study 35550374 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarectal 10-mg diazepam suppository
Number of subjects: 123
Study 35550374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 33596099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope enhancement workshop (half-day)
Number of subjects: 39
Study 32689594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15mg daily
Number of subjects: 7213
Study 32689594 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100mg daily
Number of subjects: 7213
Study 35813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nursing combined with early drinking water therapy
Number of subjects: 600
Study 35813411 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (Control)
Number of subjects: 600
Study 33478236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary artery grafts (n = 387)
Number of subjects: 772
Study 33478236 — intervention group
Group type: COMPARATOR
Intervention: Left internal mammary artery grafts (n = 385)
Number of subjects: 772
Study 35729430 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (100 mg, n=113)
Number of subjects: 233
Study 35729430 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride (starting dose: 0.5 mg, n=120)
Number of subjects: 233
Study 33499076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene board game intervention (60-min sessions, twice a week)
Number of subjects: 42
Study 33499076 — intervention group
Group type: COMPARATOR
Intervention: Control stage (pre-test and baseline measurements)
Number of subjects: 42
Study 35176533 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 20 mg three times daily for seven days
Number of subjects: 55
Study 35176533 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 40 mg three times daily for seven days
Number of subjects: 55
Study 35176533 — intervention group
Group type: EXPERIMENTAL
Intervention: CALAS 80 mg three times daily for seven days
Number of subjects: 55
Study 35176533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32728702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol consumption
Number of subjects: 40
Study 32728702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35691184 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 45
Study 35691184 — intervention group
Group type: EXPERIMENTAL
Intervention: TNES
Number of subjects: 45
Study 35691184 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 32781283 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules combined with western medicine
Number of subjects: 283
Study 32781283 — intervention group
Group type: COMPARATOR
Intervention: Lianhua Qingwen granules combined with western medicine
Number of subjects: 283
Study 32781283 — intervention group
Group type: COMPARATOR
Intervention: Western medicine alone
Number of subjects: 283
Study 35435017 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (<2 g of sodium)
Number of subjects: 98
Study 35435017 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 98
Study 35435017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 35435017 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 98
Study 34477291 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment (HT)
Number of subjects: 100
Study 34477291 — intervention group
Group type: COMPARATOR
Intervention: Inpatient Treatment-as-Usual (TAU)
Number of subjects: 100
Study 32894190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (TA)
Number of subjects: 105
Study 32894190 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 105
Study 32894190 — intervention group
Group type: COMPARATOR
Intervention: Medication (MC)
Number of subjects: 105
Study 34313948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Number of subjects: 20
Study 34313948 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 35175622 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD25 (25 mg/kg/day)
Number of subjects: 224
Study 35175622 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD50 (50 mg/kg/day)
Number of subjects: 224
Study 35175622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 33026876 — intervention group
Group type: EXPERIMENTAL
Intervention: Celebrate Safe approach (experimental condition)
Number of subjects: 3836
Study 33026876 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3836
Study 32047014 — intervention group
Group type: EXPERIMENTAL
Intervention: HELP‐CDSS (computerised clinical decision support system)
Number of subjects: 135
Study 32047014 — intervention group
Group type: COMPARATOR
Intervention: Control period (standard care)
Number of subjects: 135
Study 36255525 — intervention group
Group type: COMPARATOR
Intervention: 0.125% levobupivacaine at 8 mL/h
Number of subjects: 50
Study 36255525 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine at 8 mL/h
Number of subjects: 50
Study 33395687 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Theta-Burst Stimulation (cTBS)
Number of subjects: 28
Study 33395687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Theta-Burst Stimulation (iTBS)
Number of subjects: 28
Study 33395687 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 28
Study 33850624 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 136
Study 33850624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 35889936 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin and evening primrose oil
Number of subjects: 50
Study 33502815 — intervention group
Group type: EXPERIMENTAL
Intervention: VERVE Chews Blue Mint
Number of subjects: 0
Study 33502815 — intervention group
Group type: EXPERIMENTAL
Intervention: VERVE Chews Green Mint
Number of subjects: 0
Study 33502815 — intervention group
Group type: COMPARATOR
Intervention: CIGS (own-brand cigarettes)
Number of subjects: 0
Study 33502815 — intervention group
Group type: COMPARATOR
Intervention: GUM (nicotine polacrilex gum)
Number of subjects: 0
Study 33502815 — intervention group
Group type: EXPERIMENTAL
Intervention: Test products (VERVE Chews)
Number of subjects: 0
Study 33523128 — intervention group
Group type: COMPARATOR
Intervention: Prospective audit and feedback (PAF)
Number of subjects: 429062
Study 33523128 — intervention group
Group type: COMPARATOR
Intervention: Restrictive policies (RP)
Number of subjects: 429062